Published in J Neurol Neurosurg Psychiatry on May 12, 2010
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways. Curr Genet Med Rep (2014) 1.18
Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet (2013) 0.96
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism. PLoS One (2011) 0.91
Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis (2012) 0.89
Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord (2011) 0.85
Recent advances in Parkinson’s disease genetics. J Neurol (2014) 0.84
Current understanding of the glial response to disorders of the aging CNS. Front Pharmacol (2012) 0.82
HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population. PLoS One (2012) 0.79
Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. Int J Mol Sci (2016) 0.78
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord (2016) 0.75
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med (2008) 6.86
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet (2007) 5.09
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol (2013) 3.05
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol (2005) 2.74
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med (2012) 2.65
Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet (2010) 2.64
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg (2011) 2.53
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A (2009) 2.31
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol (2011) 2.26
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. Ann Neurol (2012) 2.15
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol (2007) 1.99
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology (2014) 1.85
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell (2013) 1.70
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol (2005) 1.62
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson's disease. Exp Neurol (2012) 1.55
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology (2011) 1.51
Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology (2013) 1.51
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation (2009) 1.49
Chromosome 7q21-22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. J Neuroimmunol (2002) 1.48
Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult Scler (2011) 1.47
Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. Acta Neurochir (Wien) (2011) 1.46
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
Image-verified deep brain stimulation reduces risk and cost with no apparent impact on efficacy. Mov Disord (2012) 1.42
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
Transplantation between monozygotic twins: how identical are they? Transplantation (2014) 1.38
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.37
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage (2011) 1.33
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27